Resources

Medical devices are a critical but often overlooked component for effective facility-based care, especially for women and children. Many medical devices have unique characteristics that make them difficult to manage effectively, particularly in low-resource settings. For instance, some devices can serve multiple clinical uses across different health programs—complicating ownership and funding responsibilities. They can sometimes require extensive training, ongoing preventive maintenance, and a reliable supply of specialized parts and accessories.This fact sheet offers an overview of the Scaling Access to Lifesaving Equipment (SCALE) project—which builds on previous research and initiatives under Market Dynamics for Medical Devices. Through this project, PATH will identify and test promising new business and operating models, while strengthening the underlying systems for managing all durable medical devices and equipment. With a vision that patients should have reliable access to device-related health services, this project seeks to ensure medical devices are available and functional in sufficient quantities across health facilities.

Microarray patch (MAP) technologies can address the need for improved presentations of vaccines. The PATH Center of Excellence for MAP Technology is advancing MAP development for high priority needs in low- and middle-income countries (LMICs). The development of a vaccine MAP depends on a number of technical, clinical, regulatory, and commercialization factors. To aid in selecting an appropriate antigen, this document overviews key antigen qualities that impact the likelihood of successful technical development for a vaccine MAP.

This document is a resource list and compendium of national-level guidelines and protocols for selected countries based on the neoLENS policy review, as of February 2022.

The objective of this target product profile (TPP) is to describe key attributes—minimal and optimal targets—for microarray patch (MAP) delivery of COVID-19 vaccines. MAPs, also known as microneedle patches, consist of hundreds or thousands of microscopic projections that deliver dry vaccine or drug into the skin.The TPP describes key attributes for such a MAP for both LMIC and HIC markets. The document has been reviewed by a broad range of PATH staff with expertise in immunology, vaccine development, clinical trials, MAP technology, vaccine delivery, and vaccine manufacturing.

The COVID-19 Primer provides examples to planners, funders, and implementers looking to utilize digital health tools for pandemic and post-pandemic response. Created to guide digital investments in support of the COVID-19 vaccination response, the Primer showcases case studies that highlight the use of data and digital health tools to support immunization service delivery.